We uncover topics around weight loss, side effects of different GLP-1 RAs, and concerns about drug access and supply, with a mainly neutral-to-positive view of GLP-1 RAs, highlighting the role of an AI-enabled pipeline to help monitor for emerging side effects, uncover public sentiment, and guide future directions for research and public health efforts

The mechanistic hypothesis: Semaglutide activates GLP-1R, appetite suppression, glycemic control Cagrilintide activates amylin receptors, appetite suppression via the area postrema, slowing of gastric evacuation Two independent mechanisms of appetite suppression a supra-additive effect In Phase 1b and Phase 2 trials the combination showed a stronger effect than either component alone : Semaglutide alone: 14.9 % (STEP-1) Cagrilintide alone (Phase 2): 10.8 % CagriSema combination (Phase 2): 15.6 % CagriSema Phase 3 (REDEFINE 1): 25.3 % CagriSema thus becomes the largest body-weight signal reported in the published incretin literature to date , stronger than Tirzepatide (22.5 % in SURMOUNT-1) and comparable to Retatrutide
Unusual breadth for a tripeptide
Cloudy Pus, bacteria, or crystals think UTIs
But alcohol is an enemy of repair: it impairs healing and collagen, spikes inflammation, and wrecks recovery sleep